Eltrombopag; Romiplostim

التفاصيل البيبلوغرافية
العنوان: Eltrombopag; Romiplostim
المؤلفون: Waddell, Joseph Farland, Dominic A. Solimando, Jaclyn King
المصدر: Hospital Pharmacy. 44:228-231
بيانات النشر: SAGE Publications, 2009.
سنة النشر: 2009
مصطلحات موضوعية: Pharmacology, medicine.medical_specialty, Romiplostim, business.industry, Stomach, Eltrombopag, Pharmacy, Urine, Gastroenterology, Bioavailability, chemistry.chemical_compound, medicine.anatomical_structure, Pharmacokinetics, chemistry, Oral administration, Internal medicine, medicine, Pharmacology (medical), CYP2C8, business, medicine.drug
الوصف: PHARMACOKINETICS Eltrombopag demonstrates dose-dependant and linear pharmacokinetics. The bioavailability is estimated as at least 52% following oral administration. Eltrombopag is best absorbed on an empty stomach; plasma concentrations may be reduced by 65% if the drug is taken with a high-fat meal. Time to peak concentration is 2 to 6 hours following oral administration. Coadministration with cations such as magnesium, aluminum, zinc, and iron may reduce absorption by as much as 70%. Eltrombopag is highly protein bound (greater than 99%). The drug is extensively metabolized in the liver via oxidation by CYP1A2 and CYP2C8, and it is glucuronidated via UGT1A1 and UGT1A3. Eltrombopag is primarily excreted in the feces (59%), with 31% excreted in the urine. The elimination half-life (t1⁄2) ranges from 9 to 35 hours. A 40% to 50% accumulation of eltrombopag may occur at doses greater than 20 mg daily. Clearance of eltrombopag is reduced by 50% in patients with moderate to severe liver dysfunction. Compared with white patients, it has been found that plasma concentrations are 70% higher in Asian pa tients and 40% higher in black patients.
تدمد: 1945-1253
0018-5787
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::ec02c8995a965de50c2f3fb4de46f793
https://doi.org/10.1310/hpj4403-228
حقوق: CLOSED
رقم الأكسشن: edsair.doi...........ec02c8995a965de50c2f3fb4de46f793
قاعدة البيانات: OpenAIRE